BINSA Act
Latest action (6 Aug 2026): Introduced
What this bill does
S. 5316 would amend title VIII of the Defense Production Act of 1950 to add biotechnology to the categories of "prohibited technology" and "notifiable technology" under that law. Title VIII establishes a framework for reviewing and restricting certain technology transactions on national security grounds; this bill would extend that framework to cover biotechnology specifically. Beyond this stated purpose, the bill's full text has not yet been published, so the specific definitions, scope, and mechanisms it would use are not yet known.
Because the details are not available, it is not yet possible to say precisely which companies, transactions, or activities would be affected, or how. In general terms, provisions like this typically affect entities involved in transactions or technology transfers subject to Defense Production Act review, but until the text is released, any specific effects should not be assumed.
The bill was introduced in the U.S. Senate on August 6, 2026, by Senator Pete Ricketts (R-NE). Its only recorded action so far is introduction. From here, it would typically be referred to a Senate committee for review; whether it advances further — through committee consideration, floor votes, and potentially the House — depends on future action that has not yet occurred. Full details of the bill's provisions should become available once its text is published.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
This bill is in the first stage of the legislative process. It was introduced into Congress on August 6, 2026. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
Common questions
- What does S. 5316 do?
- S. 5316 would amend title VIII of the Defense Production Act of 1950 to add biotechnology to the categories of "prohibited technology" and "notifiable technology" under that law. Title VIII establishes a framework for reviewing and restricting certain technology transactions on national security grounds; this bill would extend that framework to cover biotechnology specifically. Beyond this stated purpose, the bill's full text has not yet been published, so the specific definitions, scope, and mechanisms it would use are not yet known. Because the details are not available, it is not yet possible to say precisely which companies, transactions, or activities would be affected, or how. In general terms, provisions like this typically affect entities involved in transactions or technology transfers subject to Defense Production Act review, but until the text is released, any specific effects should not be assumed. The bill was introduced in the U.S. Senate on August 6, 2026, by Senator Pete Ricketts (R-NE). Its only recorded action so far is introduction. From here, it would typically be referred to a Senate committee for review; whether it advances further — through committee consideration, floor votes, and potentially the House — depends on future action that has not yet occurred. Full details of the bill's provisions should become available once its text is published.
- Has S. 5316 become law?
- Not yet. As of 6 Aug 2026, S. 5316 is introduced.
- Who sponsored S. 5316?
- S. 5316 was sponsored by Sen. Pete Ricketts [R-NE] (Republican-NE), with 1 cosponsor.
- What's the latest action on S. 5316?
- Introduced (6 Aug 2026).
Related bills in International Affairs
Directing the President, pursuant to section 5(c) of the War Powers Resolution, to remove United States Armed Forces from hostilities with Iran.
Lindsey O. Graham Sanctioning Russia and Iran Act of 2026
A resolution honoring 35 years of independence for the countries of Central Asia and recognizing the importance of the United States growing relationship with Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan.
Foreign Service Modernization Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.